SSY Group (HKG:2005) said its Choline Fenofibrate Sustained-release Capsules have received drug registration approval from China's National Medical Products Administration, according to a Thursday filing with the Hong Kong bourse.
The product is approved as a Class 4 chemical drug and has passed the consistency evaluation.
Choline Fenofibrate Sustained-release Capsules are used to lower triglyceride levels in adults with severe hypertriglyceridemia and to treat patients with primary hypercholesterolemia or mixed dyslipidemia, the filing said.